Celldex Therapeutics Inc
CLDX
NASDAQ
Biotechnology
$41.95
USD
-0.66 (-1.55%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $3.39B
Volume 849.4K
Revenue
$158,000
TTM
-97.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-300.55M
TTM
-50.6%
YoY
Operating Cash Flow
$-235.57M
TTM
-26.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.7 | 0.0 | 0.1 | 0.0 | 0.0 |
YoY Growth | -70.8% | -100.0% | -89.7% | -97.8% | -97.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.7 | 0.0 | 0.1 | 0.0 | 0.0 |
Selling, General & Administrative | 10.4 | 10.7 | 11.9 | 11.4 | 13.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 64.6 | 73.6 | 87.3 | 84.5 | 80.6 |
Operating Income | -63.9 | -73.6 | -87.2 | -84.4 | -80.6 |
EBITDA | -63.0 | -72.8 | -86.3 | -83.6 | -79.7 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 7.3 | 6.6 | 5.8 | 5.8 | 7.1 |
Income Before Income Taxes | -56.6 | -67.0 | -81.3 | -78.7 | -73.5 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -56.6 | -67.0 | -81.3 | -78.7 | -73.5 |
Consolidated Net Income / Loss | -56.6 | -67.0 | -81.3 | -78.7 | -73.5 |
Net Income Attributable to Common Shareholders | -56.6 | -67.0 | -81.3 | -78.7 | -73.5 |
Basic EPS | -$0.85 | -$1.01 | -$1.22 | -$1.18 | -$0.94 |
Diluted EPS | -$0.85 | -$1.01 | -$1.22 | -$1.18 | -$0.94 |
Basic Shares Outstanding | 66.4M | 66.4M | 66.5M | 66.6M | 77.8M |
Diluted Shares Outstanding | 66.4M | 66.4M | 66.5M | 66.6M | 77.8M |